Advances in many aspects of science including molecular biology, genomics and proteomics have resulted in significant advances in defining the causes of and new treatments for cancer. Close collaborations are needed to take advances from the laboratory into the clinic. These collaborations and resources available to conduct translational clinical research have been very productive during the current funding period. Currently, the CCSG provides funding for 0.25 FTE research nurse and 0.5 FTE clinical research specialist (CRS). The IU Simon Cancer Center has allocated this money by a process described in detail below to support investigatorinitiated Phase I and pilot studies that are highly meritorious. The ID Simon Cancer Center also provided additional funds from other sources for the conduct of these trials. We anticipate growing numbers of patients accrued to future phase I and pilot studies because of the recruitment during the current funding period of translational clinical investigators (Chiorean, Farag, Hahn, and Matei) and planned expansion of our phase I program during the next funding period. From 2004 through mid-2007, the IUSCC supported 15 clinical trials by this mechanism. Total patient accrual is to date 132. On occasion, the Center used additional funds to support individual trials. For example, additional IUSCC funds have been used to support the laboratory correlative studies associated with a trial supported by the PSR mechanism;the PSR funding has been used to support nurses and clinical research specialists. The process has been updated during the current cycle with resulting increased number of faculty conducting investigator-initiated trials. PSR support has been prioritized to protocols that will generate preliminary data that has been (or will be) used to support R21 Quick Trials and other peer-reviewed funding applications. The process to seek funding for the conduct of pilot clinical trials was updated in 2006 and is available to all IUCC members via a continuous RFA found at trial.php. The announcement details the fact that Protocol Specific Research funding covers the cost of a core group of research nurses and data managers (clinical research specialists) for the conduct of high priority, innovative, feasibility or proof-of-principle clinical trials. The requests for funding are to be used for early-phase testing of a candidate agent or device for the prevention or treatment of cancer. Applications are received and reviewed monthly by the Clinical Research Committee.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
United States
Zip Code
Broxmeyer, Hal E; Pelus, Louis M (2014) Inhibition of DPP4/CD26 and dmPGE? treatment enhances engraftment of mouse bone marrow hematopoietic stem cells. Blood Cells Mol Dis 53:34-8
Blue, Emily K; DiGiuseppe, Robert; Derr-Yellin, Ethel et al. (2014) Gestational diabetes induces alterations in the function of neonatal endothelial colony-forming cells. Pediatr Res 75:266-72
Miller, Kathy D; Althouse, Sandra K; Nabell, Lisle et al. (2014) A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. Breast Cancer Res Treat 148:99-106
Chiorean, E Gabriela; Schneider, Bryan P; Akisik, Fatih M et al. (2014) Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 89:284-91
Nudelman, Kelly N H; Wang, Yang; McDonald, Brenna C et al. (2014) Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. PLoS One 9:e96713
Hocevar, Barbara A; Kamendulis, Lisa M; Pu, Xinzhu et al. (2014) Contribution of environment and genetics to pancreatic cancer susceptibility. PLoS One 9:e90052
Chitteti, Brahmananda Reddy; Kobayashi, Michihiro; Cheng, Yinghua et al. (2014) CD166 regulates human and murine hematopoietic stem cells and the hematopoietic niche. Blood 124:519-29
Chitteti, Brahmananda Reddy; Srour, Edward F (2014) Cell cycle measurement of mouse hematopoietic stem/progenitor cells. Methods Mol Biol 1185:65-78
Chang, Hua-Chen; Lewis, David; Tung, Chun-Yu et al. (2014) Soypeptide lunasin in cytokine immunotherapy for lymphoma. Cancer Immunol Immunother 63:283-95
Speth, Jennifer M; Hoggatt, Jonathan; Singh, Pratibha et al. (2014) Pharmacologic increase in HIF1* enhances hematopoietic stem and progenitor homing and engraftment. Blood 123:203-7

Showing the most recent 10 out of 83 publications